Population health impact and cost-effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China

Hepatology

Volumn 60, Issue 1, 2014, Pages 46-55

  Toy, Mehlika ^a,b   Salomon, Joshua A ^a   Jiang, Hao ^c   Gui, Honglian ^c   Wang, Hui ^c   Wang, Jiangshe ^d   Richardus, Jan Hendrik ^b   Xie, Qing ^c  

^a Department of Global Health and Population ^*  (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c SHANGHAI JIAO TONG UNIVERSITY   (China)

^d CHILDREN S HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHINA; CHRONIC DISEASE; CHRONIC HEPATITIS; COMPUTER SIMULATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CARRIER; DISEASE COURSE; DRUG COST; FEMALE; FOLLOW UP; HEALTH IMPACT ASSESSMENT; HEALTH STATUS; HEPATITIS B; HIDDEN MARKOV MODEL; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MONITOR AND TREAT; MORTALITY; PATIENT MONITORING; POPULATION; PREVALENCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHILD; CHILD, PRESCHOOL; CHINA; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HEPATITIS B, CHRONIC; HUMANS; INFANT; INFANT, NEWBORN; LIVER NEOPLASMS; MARKOV CHAINS; MIDDLE AGED; MONITORING, IMMUNOLOGIC; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; VIRUS INACTIVATION; YOUNG ADULT;

EID: 84903162287     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26934     Document Type: Article

References (45)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11:97-107.
2. Chen JG, Zhang SW. Liver cancer epidemic in China: past, present and future. Semin Cancer Biol 2011;21:59-69.
3. Liu J, Fan D. Hepatitis B in China. Lancet 2007;369:1582-1583.
4. Liang X, Bi S, Yang W, Wang L, Cui G, Cui F, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27:6550-6557.
5. Lee W. Hepatitis B virus infection. N Engl J Med 1997;337:1733-1745.
6. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273 e1261.
7. Tai DI, Lin SM, Sheen IS, Chu CM, Lin DY, Liaw YF. Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology 2009;49:1859-1867.
8. Hadziyannis SJ. Unrevealing the natural course of the so-called "inactive HBsAg or HBV carrier state." Hepatol Int 2007;1:281-284.
9. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
10. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology 2007;45:1187-1192.
11. Lok AS, Lai CL. Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology. J Hepatol 1990;10:29-34.
12. Wang L, Wang Y, Jin S, Wu Z, Chin DP, Koplan JP, et al. Emergence and control of infectious diseases in China. Lancet 2008;372:1598-1605.
13. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010;139:1218-1229.
14. Wu B, Li T, Chen H, Shen J. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health 2010;13:592-600.
15. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010;139:491-498.
16. Shouval D, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, et al. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. J Hepatol 2009;50:289-295.
17. Haber BA, Block JM, Jonas MM, Karpen SJ, London WT, McMahon BJ, et al. Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B. Pediatrics 2009;124:e1007-1013.
18. Wah CP, Hung SS, Ka CO, Hsi LT, Yeung LT. Awareness and knowledge of hepatitis B infection and prevention and the use of hepatitis B vaccination in the Hong Kong adult Chinese population. Chin Med J 2012;125:422-427.
19. Zhiqiang G, Zhaohui D, Qinhuan W, Dexian C, Yunyun F, Hongtao L, et al. Cost of chronic hepatitis B infection in China. J Clin Gastroenterol 2004;38:S175-178.
20. Lok AS. Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? J Gastroenterol Hepatol 2011;26:221-227.
21. Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med 2011;26:239-244.
22. Kanwal F, Farid M, Martin P, Chen G, Gralnek IM, Dulai GS, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006;101:2076-2089.
23. Lin X, Robinson NJ, Thursz M, Rosenberg DM, Weild A, Pimenta JM, et al. Chronic hepatitis B virus infection in the Asia-Pacific region and Africa: review of disease progression. J Gastroenterol Hepatol 2005;20:833-843.
24. Chen YC, Chu CM, Liaw YF. Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology 2010;51:435-444.
25. Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008;135:1192-1199.
26. Chu CM, Liaw YF. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol 2009;104:1693-1699.
27. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
28. Chen JD, Yang HI, Iloeje UH, You SL, Lu SN, Wang LY, et al. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010;138:1747-1754.
29. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005;142:821-831.
30. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008;48:335-352.
31. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-1010.
32. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-1020.
33. Colonno RJ, Rose RE, Pokornowski K, Baldick CJ, Eggers B, Xu D, et al. Four year assessment of entecavir resistance in nucleoside naïve and lamivudine refractory patients. J Hepatol 2007;46:S294.
34. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-1514.
35. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-1531.
36. Fleurence RL, Hollenbeak CS. Rates and probabilities in economic modelling: transformation, translation and appropriate application. Pharmacoeconomics 2007;25:3-6.
37. National Bureau of Statistics of China. Available from: www.stats.gov.cn/english.
38. China Liver Transplant Registry. Available from: www.cltr.org.
39. Levy AR, Kowdley KV, Iloeje U, Tafesse E, Mukherjee J, Gish R, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and uninfected persons. Value Health 2008;11:527-538.
40. World Health Organization. WHO guide to cost-effectiveness; 2003. Geneva, Switzerland: WHO.
41. World Bank. China overview. 2012. Available from: http://www.worldbank.org/en/country/china.
42. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health 2008;11(Suppl 1):S11-S22.
43. Chotiyaputta W, Peterson C, Ditah FA, Goodwin D, Lok AS. Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol 2011;54:12-18.
44. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, et al. Direct economic burden of hepatitis B virus related diseases: evidence from Shandong, China. BMC Health Serv Res 2013;13:37.
45. Chao J, Chang ET, So SK. Hepatitis B and liver cancer knowledge and practices among healthcare and public health professionals in China: a cross-sectional study. BMC Public Health 2010;10:98.